Serenoa repens induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of STAT 3 signaling

Oncology Reports

Volumn 22, Issue 2, 2009, Pages 377-383

  Che, Yuqin ^a   Hou, Shuai ^a   Kang, Zhiwei ^a   Lin, Qiao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Multiple myeloma; Serenoa repens; Signal transducer and activator of transcription 3

Indexed keywords

DOCETAXEL; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P27; SABAL EXTRACT; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SABAL; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIPLE MYELOMA; PHOSPHORYLATION; PHYTOTHERAPY; SERENOA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TAXOIDS; TYRPHOSTINS;

EID: 68349110517     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000448     Document Type: Article

References (41)

1. Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med 351: 1860-1873, 2004.
2. Katzel JA, Hari P and Vesole DH: Multiple myeloma: charging toward a bright future. CA Cancer J Clin 57: 301-318, 2007.
3. Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937, 2002.
4. Gorschluter M, Ziske C, Glasmacher A and Schmidt-Wolf IGH: Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Clin Cancer Res 7: 2195-2204, 2001.
5. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
6. Darnell JE Jr: STATs and gene regulation. Science 277: 1630-1635, 1997.
7. Ihle JN and Kerr IM: Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 11: 69-74, 1995.
8. Ihle JN: STATs and MAPKs: obligate or opportunistic partners in signaling. Bioessays 18: 95-98, 1996.
9. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R and Loughran TP: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362, 2001.
10. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002.
11. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
12. Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ and Huang HF: IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer 1: 19, 2001.
13. Risberg T, Lund E, Wist E, Kaasa S and Wilsgaard T: Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 16: 6-12, 1998.
14. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR and Delbanco TL: Unconventional medicine in the United States - prevalence, costs, and patterns of use. N Engl J Med 328: 246-252, 1993.
15. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M and Kessler RC: Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up National Survey. JAMA 280: 1569-1575, 1998.
16. Gerber GS and Fitzpatrick JM: The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int 94: 338-344, 2004.
17. Wilt TJ, Ishani A, Rutks I and MacDonald R: Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3: 459-472, 2000.
18. Wadsworth TL, Carroll JM, Mallinson RA, Roberts CT Jr and Roselli CE: Saw Palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 145: 3205-3214, 2004.
19. Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K and Hirano K: Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 47: 59-65, 2001.
20. Vacherot F, Azzouz M, Gil-Diez-De-Medin S, Colombel M, De La Taille A, Lefrere Belda MA, Abbou CC, Raynaud JP and Chopin DK: Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate 45: 259-266, 2000.
21. Goldmann WH, Sharma AL, Currier SJ, Johnston PD, Rana A and Sharma CP: Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 25: 1117-1124, 2001.
22. Hostanska K, Suter A, Melzer J and Saller R: Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res 27: 873-881, 2007.
23. Yang Y, Ikezoe T, Nishioka C, Bandobashi K, Takeuchi T, Adachi Y, Kobayashi M, Takeuchi S, Koeffler HP and Taguchi H: NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br J Cancer 95: 1653-1662, 2006.
24. Yang Y, Ikezoe T, Nishioka C, Taguchi T, Zhu WG, Koeffler HP and Taguchi H: ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. Cancer Sci 97: 1404-1409, 2006.
25. Yang Y, Ikezoe T, Zheng Z, Taguchi H, Koeffler HP and Zhu WG: Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol 31: 593-600, 2007.
26. Friedenberg WR, Graham D, Greipp P, Blood E and Winston RD: The treatment of multiple myeloma with docetaxel (an ECOG study). Leuk Res 27: 751-754, 2003.
27. Ikezoe T, Chen SS, Yang Y, Heber D, Taguchi H and Koeffler HP: PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. Int J Oncol 23: 1461-1470, 2003.
28. Ikezoe T, Yang Y, Saitoh T, Heber D, McKenna R, Taguchi H and Koeffler HP: PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/ EBPbeta in non-small cell lung cancer cells. Int J Oncol 29: 453-461, 2006.
29. Liu JJ, Huang RW, Lin DJ, Peng J, Zhang M, Pan X, Hou M, Wu XY, Lin Q and Chen F: Ponicidin, an ent-kaurane diterpenoid derived from a constituent of the herbal supplement PC-SPES, Rabdosia rubescens, induces apoptosis by activation of caspase-3 and mitochondrial events in lung cancer cells in vitro. Cancer Invest 24: 136-148, 2006.
30. Sartippour MR, Seeram NP, Heber D, Hardy M, Norris A, Lu Q, Zhang L, Lu M, Rao JY and Brooks MN: Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol 26: 121-127, 2005.
31. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffler HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23: 1187-1193, 2003.
32. Ikezoe T, Chen SS, Heber D, Taguchi H and Koeffler HP: Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49: 285-292, 2001.
33. Bromberg J and Darnell JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473, 2000.
34. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
35. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197: 157-168, 2003.
36. Hodge DR, Hurt EM and Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512, 2005.
37. Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548-2556, 2000.
38. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O and Tanaka H: Autocrine generation and requirement of BSF-2/ IL-6 for human multiple myelomas. Nature 332: 83-85, 1988.
39. Frassanito MA, Cusmai A, Piccoli C and Dammacco F: Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells. Br J Haematol 118: 157-165, 2002.
40. Bommert K, Bargou RC and Stuhmer T: Signalling and survival pathways in multiple myeloma. Eur J Cancer 42: 1574-1580, 2006.
41. Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M and Sebti SM: Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105: 4759-4766, 2005.